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v.A.: What do you see ahead for R.P.L.: I anticipate a period of renewed growth after a time in the seventies 
the pharmaceutical industry? when the industry experienced a somewhat flatter period than it had been 
accustomed to. This will result, I think, from the converging effects of several 
factors. First, you have to remember that the research cycle is not a linear 
process, unlike a production process where you put in so many widgets, the 
line moves along at a predetermined rate, you add so much labor and out 
pops the product. 
Research is a demanding, creative process, although it does have a natural 
rhythm, a cyclical pattern. The process also depends to a certain extent on 
accumulating a reservoir of knowledge which can be exploited. Right now, for 
instance, a whole new base of knowledge in biology is emerging. Perhaps for 
the first time, the function of cell receptor sites is being defined and under-
stood. Concurrently, we are also building a whole new discipline focusing oh 
the "tools" to exploit this new biological knowledge, such as the recombinant 
DNA technology that has only become commercial within the last year or two. 
We are learning at an accelerating rate, and so we're coming to a point in the 
history of this industry where we are going to have quantum increases in the 
type and number of products coming to market. If you look at most forecasts, 
the consensus is that the industry is going to grow from the 1980-81 level of 
$75 to $80 billion worldwide to a $145 to $150 billion level by the end of the 
decade, 1990. This represents a real growth rate of about 6 percent, which is 
better than we experienced in the 70s. In the 1970s, the real growth rate— 
depending again on whom you talk to—was probably AVi to 5 percent. So I 
think we are coming to a pretty healthy period for the industry from the stand-
point both of new products and sales and profits. 
In this special DH&S Reports interview with 
Morristown partner-in-chief Vic Albrecht, 
Schering-Plough Corporation President and 
Chief Executive Officer Robert R Luciano 
explores the current state of the drug industry 
and new drug development, the outlook for the 
future, and, most especially, Schering-Plough's 
role as an international marketer of phar-
maceutical and consumer products. 
Mr. Luciano, an attorney, held high-ranking 
positions with several leading pharmaceutical 
companies before joining Schering-Plough as 
senior vice president for administration in 1978. 
He was named president and chief operating 
officer in October 1980, and has held the post 
of president and chief executive officer since 
February of this year. 
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Schering-Plough Corporation: a profile in brief 
S chering-Plough Corporation, by its own defini-tion, is "a research-based pharmaceutical com-pany whose worldwide business is enhanced by leading brand-name consumer products!' Based in Kenilworth, N.J., the Fortune 200 corporation has some 27,000 employees and 
operates manufacturing facilities in more than forty 
countries. Sales in 1981 exceeded $1.8 billion. 
Following recent fundamental advances in the recombi-
nant DNA and immunological sciences, Schering-Plough 
carefully evaluated the commercial potential of these 
new technological approaches and moved decisively to 
capitalize on them. 
Schering-Plough has already established itself as a 
leader in the highly promising and exciting area of re-
search focusing on genetically produced interferon, a 
substance that holds great promise as both an anti-
cancer and antiviral agent. 
In the field of immunological sciences, the company 
has targeted three specific areas on which most of its 
efforts will concentrate during the next five to ten years. 
These are: 
Immunomodulation, where the goal is to identify and 
produce entities that are specific suppressors or in-
ducers of the body's immune response. This research 
may provide new knowledge for the treatment of dis-
eases ranging from rheumatoid arthritis and multiple 
sclerosis to cancer. 
Allergy, where a key objective is to identify and pro-
duce substances that will prevent an allergic response 
by the body rather than merely block the effects of 
histamine after that substance has already been 
released in the body. 
Infectious diseases, where the effort is directed 
toward identifying and producing substances that 
will stimulate the production of an antibody that is 
the human body's main defense against a broad 
spectrum of infectious diseases. 
Schering-Plough's well-known consumer products 
include Maybelline eye, lip, face and nail cosmetics; 
the Coppertone line of sun-protection lotions and 
Solarcaine sunburn medications; Scholl foot-care prod-
ucts; Correctol laxatives; Duration nasal spray; Di-Gel 
tablets; Sardo bath products; and Paas Easter activity 
toys. In mid-October, Maybelline will enter the fragrance 
market and has scheduled a $3.5 million advertising 
campaign to launch Daydreams, a medium-priced fra-
grance developed by Maybelline's research laboratories 
in cooperation with top fragrance houses. 
Other divisions of Schering-Plough include animal-health 
products; vision-care products, such as the hard and 
soft contact lenses marketed under the Wesley-Jessen 
brand; DAP home products; and Plough Broadcasting, 
which operates six AM and six FM radio stations. • 
V.A.: With this kind of potential for 
achievements in medical science 
and your company's record as a 
major innovator in the pharma-
ceutical industry, what is Schering-
Plough's plan to enhance its future 
and improve its position as a world 
leader in the health and personal-
care fields? 
R.P.L: We view ourselves first and foremost as an ethical, research-based phar-
maceutical company. If that is our principal or core business, that's what our 
strategy for growth has to revolve around—and it does revolve principally 
around research. We have increased significantly the financial resources de-
voted to our research programs. These expenditures have been growing at a 
compound growth rate of about 20 percent a year for the last two to three 
years. They will probably grow about 20 to 21 percent this year, and I would 
look for a compound growth rate over the next five years in the range of 15 to 
18 percent annually. 
In addition to putting more dollars to work, we have concentrated the re-
search program on several major areas. If you have a nonfocused program, no 
matter how much money you pour in, you will dilute your efforts and waste 
those valuable funds. The paths you can pursue are so varied and so many 
that, even with a fairly substantial budget, and ours will be about $130 million 
this year, you have to concentrate your activities. So we streamlined the pro-
gram from eight or nine areas that the company was working in several years 
ago to four basic areas of concentration; namely anti-infectives, cardiovascu-
lar, anti-inflammatories and allergies. And we defined it even further by 
selecting specific targets in those four areas toward which we intend to direct 
our activities. The newly developing technology that I mentioned earlier lends 
itself very nicely to the accomplishment of results in our target areas. For 
example, we are fairly heavily involved in the recombinant DNA field, as you 
know, first through our investment in Biogen, an international organization of 
genetic scientists, and second through our development of an in-house R&D 
capability and manufacturing capacity. 
As part of our research realignment, we also decided to actively pursue our 
interest in the field of immunology, which was growing at a very rapid rate. 
The tools used in recombinant DNA technology can also be applied to the 
field of immunology, and, conversely, some of the tools developed to be used 
in immunology complement the skills used in the recombinant DNA area. So 
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for us it involved an increased financial commitment to coincide with our 
redirected strategic thrust. We have also restructured our personnel and 
improved things tremendously through a number of changes in key man-
agerial slots. And last, but not least, we put in management systems that 
enable us to track a program financially as well as in terms of objectives, to 
have finite cutoff points so that a program doesn't go on forever just because 
it was started. We are using new management tools for the periodic measure-
ment of accomplishments against predetermined goals, and we know where 
we are going and how we are going to get there. To sum up, intensified and 
targeted research is our principal strategy for the company. In the final analy-
sis, research is the essential core of our business. 
v.A.: How does the recent acquisi-
tion of DNAX (a biotechnology 
research firm concentrating on 
immunology and genetic engineer-
ing) fit into Schering-Plough's 
overall research strategy? 
R.RL: As part of our program to establish a capability in immunology, we set 
up several task forces to study both the scientific feasibility of various areas 
in which developments were most likely to take place in the 1980s and to 
assess the commercial attractiveness of those areas. The task force that 
looked at immunology identified a program which we thought was quite inter-
esting, and we were setting out to pursue it by constructing a laboratory in 
France and building an immunology infrastructure from the ground up. Some 
of the skills necessary had to be recruited from outside the company. By pure 
coincidence, I received a phone call about a possible joint venture with the 
DNAX people on a specific project. 
When our people began talking to the DNAX group, they developed a growing 
appreciation for the caliber of scientific talent that had been assembled at 
DNAX within the one year of its existence. That particularly talented body of 
people represented a really valuable asset, one that, if we were to build at all, 
could only be assembled over a period of years and perhaps couldn't be built 
at all within an internal industrial setting like ours. It really required a quasi-
university environment. 
One thing led to another as we described our program to them and they 
described their capabilities and interests to us. Each group became impressed 
by the other, and we concluded that Schering-Plough could expedite our in-
house building process and perhaps gain two or more years in developing an 
immunology infrastructure of a quality that perhaps we might never have 
achieved. So DNAX enabled us to do earlier what we had already decided to 
do. They adopted our program, and adopted it wholeheartedly, I might add. So 
for us, it was a shortcut in a race which I think is going to go to the swiftest. 
v.A.: In view of the presently 
clouded picture regarding patents 
in biotechnology, how does 
Schering-Plough view the issue 
of patent protection? 
R.RL: Schering-Plough and most pharmaceutical companies, most research-
based companies, have a large investment in the development of technology. 
We have a policy of respecting patents in any field in which we're active, as 
do our competitors. This policy is one that, because of self-interest, will not be 
abandoned lightly by anybody. The record will demonstrate that our patent 
position, for example in the interferons, which was the first of our recombi-
nant projects, is based on what we have been able to research and produce 
better than anyone. I have never been prepared to concede that valid, enforce-
able patents would not issue through this technology. I remember when I first 
started talking about this in January or February of 1980, I got a lot of ques-
tions from the security analysts regarding patentability. I took the position 
then, and I take it now, that valid patent protection will issue. That has been 
justified in part by the patent position in the case of the General Electric 
research scientist who developed an organism that eats oil slicks. 
The fundamental question of the patentability of the living organism was ad-
dressed by the Supreme Court, and it was found to be patentable. That case 
21 
did not dispose of all the issues, but I think it indicates that we're moving in 
the right direction. The issuance to Stanford University of some of the basic 
process patents is another indication that we're moving in the right direction. 
Logically, there should be valid patent protection in the field. I think the record 
indicates that, in the case of the interferons at least, Schering-Plough is going 
to achieve a superior position. 
V.A.: Realistically, when can we ex-
pect to see new pharmaceuticals 
emerging from Schering-Plough's 
research in biotechnology? 
R.RL: When we first announced our collaboration with Biogen in the develop-
ment of leucocyte interferon, we set a timetable of having a product on the 
market in 1984-85. That was a very ambitious target because, if you look at 
studies of the development of a pharmaceutical product, the normal time 
from inception to marketing is about ten or ten-and-a-half years. In early 1980, 
we were projecting four to five years, so I think you can appreciate that this 
was a very, very aggressive time schedule. We slipped behind at several 
points, but we made up time at others, and we're right on schedule now. I 
think we're likely to see an interferon product on the market in 1984. With 
respect to products from some of our other biotechnology investments, such 
as DNAX, we recognize that this project is a long-term investment. Our time-
frame, therefore, is to have a marketable product in five to ten years. I think 
we'll see products being tested in the clinics in three to five years, and I think 
we'll see products on the market in five to ten years. As an optimist, I'd say 
less than ten years, but that remains to be seen. 
V.A.: With respect to the restraining 
effects of government regulatory 
activities on pharmaceutical re-
search, has the current administra-
tion fulfilled its promise to remove 
unnecessary barriers to new drug 
discovery? 
R.RL: The present administration, particularly with the appointment of Dr. 
Arthur Hayes as Commissioner of the Food and Drug Administration, took a 
giant step forward in regulatory matters. Dr. Hayes is a competent, realistic 
administrator. I think the process of easing the regulatory pathways is going to 
be a longer one, however, than the administration anticipated and the industry 
hoped for when this administration came to office. But some steps already 
have been taken in that direction. The antibiotic certification program has es-
sentially been abolished, and, quite recently, Secretary of Health and Human 
Services Richard Schweiker announced a complete reorganization of the new 
drug application process, which embodies within it a number of features long 
sought by the industry. For example, in the past, even with good, valid clinical 
data from European sources, we had to duplicate the work. The FDA would 
approve drugs only on the basis of U.S. experience, U.S. tests, regardless of 
the validity of overseas testing. 
That began to change two or three years ago, and this year the agency did 
approve an indication for a new product solely on the basis of foreign, in this 
case Norwegian, data. It's now official FDA policy to accept foreign data if the 
studies have been conducted properly. That's a giant step forward. That is 
going to save a lot of needless duplication. The mechanical process of review-
ing a new drug application has taken between two to three years—and that's 
just to review an application once it has been filed. The process has been one 
of reviewing it seriatum—you review your whole section in chemistry, I re-
view my section of biology, somebody else review his... one after the other. 
The new process espouses a concept that we've been after for a long time, 
concurrent review, which is a logical process. 
Also, there was no effective appeal from a reviewer's determination on a sci-
entific point within your application. If he didn't agree with your conclusion and 
wanted more data, you went out and got more data because there was no 
other way of approaching the problem, no workable appeal mechanism within 
the system. The new proposal, I understand, is going to provide a mechanism 
for appeal to a board of FDA scientists and outside independent scientific ex-
perts who will review the subject of any disputed scientific material and make 
a determination as to who is right or wrong. This is sorely needed. There are 
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Robert Luciano 
on drug research... 'the needfor a clear strategy, a clear focus' 
"New drug development requires 
a very heavy investment in re-
search. Schering-Plough spends 
about $130 million a year, and 
we're by no means the biggest 
spenders. The time required to de-
velop a new drug may easily be 
ten years, so you have to invest a 
lot of money year after year after 
year. In the past, these outlays 
were made on faith, as if to say: 
'We had a drug before and we II 
certainly have one again'. And 
maybe, if you went from year to 
year, just on the basis of sheer 
volume, it eventually did happen. 
"But I think we'll see a winnowing 
of companies in the 80s, because 
the research process is becoming 
more expensive, and the return on 
investment—// you want to look at 
it purely in those terms—becomes 
more and more difficult to justify 
unless you have a certain 'critical 
mass'. 
Although it finally seems to be 
changing, government policy has 
made the drug development and 
testing process more expensive 
and more involved. And this is 
while, at the same time, the gov-
ernment talked about wanting to 
increase competition. After ten, fif-
teen, even twenty years of policy 
that's been highly restrictive, the 
government has produced the op-
posite effect—and only those com-
panies with a clear strategy, a clear 
focus and sound resources and 
talent are really going to make it" 
* m,. 
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lots of steps which could shorten the process. Take a very mundane example: 
new drug applications literally require truckloads of data because we are re-
quired to supply every single clinical form, and there may be three or four 
thousand patients. Every time they visit a doctor, there's another form filled 
out. We've supplied every piece of paper that's required. We've argued for 
years that we should be able to provide summaries of the data and have the 
other material available should the reviewer want to see it. The summaries 
would be akin to the material we now provide in scientific publications— 
detailed summaries of some fifty to 200 pages. That has not been acceptable 
in the past. Everybody wanted the raw data so they could start from day one 
and build up their own analysis. Under the new proposals, the raw data will be 
available but summaries will be acceptable. There should be appropriate 
penalties for anyone providing a summary which does not accurately reflect 
the data in the package; that's only fair and reasonable. But the summaries 
will make things a lot easier for everyone. So, yes, the administration is mov-
ing in the direction of reform, but just announcing those steps is only the first 
part. Implementing them, changing the basic structure, is going to take a long 
time. There are no shortcuts. But the goal of this program is to reduce the 
timeframe for review by six months. This doesn't sound like a lot, but it is, and 
it would be a big step forward. 
v.A.: In the light of an apparent 
worldwide recession, what is the 
outlook for the international seg-
ment of Schering-Plough's 
operations? 
R.RL: International operations are one of our bright spots. Schering-Plough is a 
fairly well-balanced company, with almost half our sales coming from over-
seas. There are recessionary problems in many of the countries we deal with 
now, and, of course, the problems of hyperinflationary economies in Argentina 
and Brazil. But, with the global scope of our business, problems in one place 
are usually offset someplace else. And we haven't fully exploited the oppor-
tunities available to us overseas, particularly on the consumer side of our busi-
ness, which has not been as fully developed overseas as our pharmaceutical 
business. So the opportunities for growth overseas, in spite of current, essen-
tially cyclical economic problems, are enormous. 
v.A.: Like many international com-
panies, Schering-Plough's earnings 
have been severely impacted by 
the stronger U.S. dollar. What 
steps have you taken to minimize 
the effects of currency fluctuations 
on Schering-Plough's profits? 
R.RL: We've done a number of things. We adopted FASB52 in 1982, which, 
while not perfect from Schering-Plough's perspective, does represent an im-
provement. I say not perfect from Schering-Plough's perspective because, as 
you know, the new rule still treats hyperinflationary economies much as the 
old FASB8 did, and a large portion of our investment in South America hap-
pens to reside in two hyperinflationary economies, Argentina and Brazil. 
Moreover, the new rule, unlike the old, requires the recognition of gains and 
losses on currency which still flow through the profit-and-loss statement. So 
while our exposure has been moderated, it certainly hasn't been dramatically 
affected by FASB52. Therefore, we've engaged in many of the transactions 
that companies in this situation resort to—typical hedges, some currency 
swaps, forward contracts and balancing our exposure abroad by having loans 
in local currencies. But it's very, very difficult to significantly impact a number 
of our exposures because, while hedges are available, the economics at any 
particular time may dictate that you not take certain steps. That is to say, the 
cost of the transaction may be greater than the potential currency loss. So 
while we've moderated our losses, we've still experienced a fair degree of 
problems from the fluctuation of currency, particularly with the continued 
strengthening of the U.S. dollar. 
v.A.: In recent years Schering-Plough 
has engaged in a number of ac-
quisitions. Do you envision any 
major acquisitions or other signifi-
cant moves to expand business 
opportunities over the near term? 
R.RL: We have a formal acquisition program and we've been relatively active. 
We've made 12 acquisitions of various sizes, from a sales volume of $10 
million up to sales of $300 million, since January 1978. We will continue to 
look for a company that fits our philosophy of doing business, and one which 
will enable us to achieve more easily our goals and objectives. But we're not 
going to purchase a company just for the sake of growing in size or because it 
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seems fashionable. However, based on our past track record, which I think 
has been good, if we uncover a good fit for us through our efforts, we'll 
pursue it. 
v.A.: What do you consider to be 
Schering-Plough's major strengths? 
R.RL: There are several. One is balance. We are balanced between interna-
tional and domestic operations fifty-fifty. We are also balanced between 
consumer and pharmaceutical operations roughly in the same ratio. So we do 
have balance. A cyclical downturn or geographical problem in one segment 
may be offset by the other. We also have a very strong balance sheet, which 
enables us to pursue our objectives without undue concern. In both segments 
of the business, consumer and pharmaceutical, we have achieved a degree 
of marketing expertise which I think is as good or better than just about any-
one's. The record of both those groups demonstrates that. And we've 
achieved, in both segments of the business, a reputation for quality which 
enables us to develop new products that are readily accepted by the consum-
ing public and by the physician. In addition, we've completed a restructuring 
of our management and a recruitment of several key executives that gives us 
a management team to exploit those strengths in the 1980s. I think those 
essentially represent our key strengths. 
v.A.: In building a management 
team, what qualities do you look 
for in key personnel? 
R.RL: First of all, you've got to have someone who has a high degree of intel-
ligence and knowledge about the business segments you're asking him to 
devote his skills and talent to. That means someone who can think strate-
gically looking beyond day-to-day problems; someone who can map out a 
plan, a direction in which you want to take the business and then stick to and 
implement that plan consistently and creatively. By creatively, I mean not 
being wed to practices that we've grown up with just because we have 
grown up with them. I mean being willing to explore new ideas, to fail in 
some new ideas, to try different approaches when one does fail. 
The qualities I look for in a manager include flexibility and, most important, a 
willingness and a confidence in his or her own ability to make decisions. Too 
many people avoid decisions and let events take their own course. I'd rather 
have somebody who's making decisions actively, even if he's making them 
occasionally differently than I would. I'd rather have him actively managing the 
business than taking a passive approach. And last but not least, you have to 
look for compatibility. No matter how intelligent, how competent a manager 
is, if he doesn't fit in with the rest of the team, if he doesn't contribute out-
side of his own area, if he's a narrow specialist with little interest in the 
business as a whole—then you're going to miss some of that interplay that 
serves as a check and balance on other people and is so vital in any dynamic, 
progressive organization. 
V.A.: How do consumer products 
fit into the overall operation of 
Schering-Plough? 
R.RL: One of the strengths of the company, as I noted, is that we are balanced 
between pharmaceuticals and consumer products. Our consumer operations 
are based fundamentally on well known and respected brand-name franchises 
that allow us to ride out occasional weaknesses that may develop in the gen-
eral marketplace. For example, in our Maybelline cosmetic business—one of 
our stars—we've grown consistently in the last several years at a faster rate 
than the cosmetics industry as a whole. The paramount reason is that we 
continually provide a high-quality product at moderate prices. This is largely 
attributable to our successful mass-merchandising approach that is supported 
fully by strong and innovative advertising campaigns. Even in a recessionary 
economy, a woman is more likely to switch to a more moderately priced 
quality product than give up cosmetics. We provide that lower-priced quality 
product, we fill that niche. 
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The management group in our Maybelline operation is typical of our other 
consumer operations—it's an aggressive management that's looking for 
niches to fill in the marketplace. They found an opening for a moderately 
priced fragrance and, at the end of this year, we're introducing a new fra-
grance, a daring move at this particular time. But I think we've planned it out 
well, and I think we'll succeed with the plan. 
The rest of the organization has also been searching out niches. We domi-
nated the sun-care market, with a 46 percent share last year. We've taken a 
market which used to be thought of as essentially suntan oil and we've seg-
mented it. We came out with Tropical Blend lotion which went after the youth 
market. We developed a series of products for the winter markets, such as 
skiing. Recently, we came out with a product called For Faces Only, which 
was formulated specifically in response to consumer's needs from the stand-
point of scent, nongreasy properties and moisturizing properties. And so 
we've continued to grow in a market that had been relatively stagnant, one in 
which we dominate by segmentation and niching. Our people have done an 
exceptionally good job. 
On the proprietary drug side of the business, we benefit from demographics. 
As the population grows older, as medical care becomes more expensive, 
people turn more to self-medication, and we have a number of products 
which address themselves to these needs and wants. The consumer prod-
ucts side of our business complements very well the pharmaceutical side— 
it's been a very good fit for us. 
v.A.: In laying out a roadmap for 
the restoration of American indus-
trial leadership, what do you see 
as some of the basic problems? 
R.RL: Americans tend to look for quick fixes. Whether the question is produc-
tivity or the Japanese, we always look for the quick solution to the problem. 
Right now the fashion is to emulate the Japanese because they are seen as 
doing everything so well. If you really think about what the Japanese do, if 
you study them carefully, you find that their attitudes and methods are tied 
closely to a culture that's been developing for several thousand years in one 
direction—a direction which is different from our own, not necessarily worse, 
not necessarily better, but different. Some of the things they do make sense, 
and we should adopt them. The quality-circle idea—which, incidentally, ori-
ginated in the United States—has been utilized extremely well by the 
Japanese. The quality-circle idea is a good one and we have adopted this 
approach at Schering-Plough. 
But to emulate everything the Japanese do is neither desirable nor necessary. 
One of the things we should emulate—and it's not necessarily a Japanese 
trait because I first became familiar with it while working for a European com-
pany—is a longer-term view of business operations than Americans custom-
arily take. American management is driven by quarterly reports, from one 
quarter to the next. That can be unhealthy because the result may lack a 
coherent, long-term strategy. We must adopt a long-term strategy, know what 
we want to be, have an idea of how we're going to get there and then pursue 
that goal. We have to be willing to live with the short-term ups and downs 
involved in pursuing that strategy. Of course, we can't totally ignore the pres-
ent—not if we want to survive. But the principal emphasis should be on the 
evolution of a consistent, coherent, intelligent strategy. That's what we're 
doing, for example, with our research program. As I said earlier, we've in-
creased our research expenditures between 20 and 22 percent annually for 
the last few years. Last year, even with profits down, we did not depart from 
that strategy We know what we want to be, we know how to get there, we 
have an intelligent plan and we're going to pursue it consistently. That doesn't 
mean we will ignore year-to-year earnings—but they're not going to be the 
driving force. • 
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